Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors inside the central anxious program, conolidine modulates alternate molecular targets. A Science Advances review found that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://bookmarksfocus.com/story6504134/details-fiction-and-conolidin-to-replace-traditional-painkillers